Pressure Bioscience (OTCMKT:PBIO) has agreed an exclusive co-marketing agreement with SCIEX, a life science analytical technologies group, which will see the new partners promote pressure cycling technology (PCT) systems.
The systems allow scientists to better extract proteins and other biological matter from cells, and that potentially yields superior biological insights.
Through the new relationship SCIEX says it will be uniquely positioned to address major challenge in complex sample preparation by marketing a complete solution.
Specifically, the agreement will see the PCT-HD system, developed by Pressure Bioscience, along with SCIEX analytic systems such as SWATH, TripleTOF, QTRAP and Triple Quad.
SCIEX highlighted that the combination of the technologies can allow proteome analysis results within 12 hours from the start of processing, which it says is much faster than current methods.
Mark Cafazzo, SCIEX director of academic and clinical research business, said the venture can deliver a powerful method to “industrialize” proteomics research.
“By partnering with PBI and adding the PCT technology to SCIEX next-generation proteomic solutions, we help scientists address the sample preparation challenges they face every day, especially when working with difficult tissue samples,” Cafazzo said.
“The net result is more comprehensive protein quantitation from complex samples, increased productivity and higher quality results.
“This is an exciting step forward for the field of proteomics, one that offers the potential to make a great and lasting impact on the quality of human life.”
Meanwhile, Pressure Bioscience chief executive Richard Schumacher added: “Bringing the PCT platform into the research laboratory enables scientists to efficiently and reproducibly break apart tissue samples and greatly accelerate their processing.
“By combining these methods with SCIEX’s expertise and successful history in mass spectrometry system solutions, clinical researchers will be equipped to make major leaps forward in proteomic analysis, over the current limitations of traditional methods.”
News of the new tie-up comes after Pressure Bioscience yesterday lifted the bar on its fund raising.
The company told investors on Monday that it had increased the capacity of its equity offering up to US$6.25mln, from US$5mln, following the receipt of US$255,000 from a hedge fund in the fifth under the placement.
Most of the cash proceeds have been used to eliminate variable-rate convertible debt, which has in turn strengthened the group’s balance sheet.